Cibus Inc (NASDAQ:CBUS) Q2 2025 Earnings: Revenue Misses but Loss Narrower Than Expected

Cibus Inc (NASDAQ:CBUS) Reports Q2 2025 Earnings: Revenue Misses Estimates, Loss Narrower Than Expected

Cibus Inc, a San Diego-based agricultural technology firm specializing in gene-edited plant traits, reported its second-quarter financial results for 2025. The company posted revenue of $930,000, falling short of analyst estimates of $1.17 million. However, its net loss per share came in at -$0.61, better than the anticipated -$0.71.

Key Financial Takeaways

• Revenue: $930K vs. $1.17M estimate (20.5% miss)
• EPS: -$0.61 vs. -$0.71 estimate (14.4% better than expected)
• Cash Position: $36.5 million as of June 30, 2025, with an expected runway into Q2 2026.

The narrower-than-expected loss suggests cost-cutting measures are taking effect, as the company reduced R&D and SG&A expenses year-over-year. However, the revenue shortfall indicates slower-than-anticipated commercialization progress.

Market Reaction

Following the earnings release, Cibus shares showed no significant after-hours movement, suggesting a neutral investor response. Over the past month, the stock has declined 15%, reflecting broader skepticism around pre-revenue biotech firms amid tightening capital conditions.

Business Highlights from the Earnings Report

1. Rice Herbicide Tolerance Traits (HT1 & HT3)

   • On track for commercial launch in Latin America by 2027, expanding to the U.S. in 2028.
   • Signed a collaboration with Colombian rice seed company Semillano.
   • Potential annual royalties exceeding $200 million upon full commercialization.

2. Sustainable Ingredients Program

   • Expects "nominal revenues" in 2025, with commercial expansion targeted for 2026.

3. Regulatory Progress

   • Favorable rulings in Ecuador, India, and the U.S. support gene-edited crop adoption.
   • USDA-APHIS cleared Cibus’ HT2 canola trait, removing a key U.S. commercialization hurdle.

4. Capital Raise

   • Generated $27.5 million in gross proceeds from a public offering, extending cash runway.

Outlook vs. Analyst Estimates

While Cibus did not provide formal forward guidance, analysts project:

• Q3 2025 Revenue: $1.29M
• Q3 2025 EPS: -$0.70
• Full-Year 2025 Revenue: $5.59M
• Full-Year 2025 EPS: -$2.94

The company’s progress in Rice HT traits and cost discipline may position it for improved financial performance, but revenue generation remains a critical hurdle.

Conclusion

Cibus’ Q2 results reflect a mixed picture—better cost control but slower revenue growth. Investors appear cautious, given the stock’s recent underperformance. The company’s long-term potential hinges on successful trait commercialization and regulatory tailwinds.

For more detailed earnings estimates and historical performance, visit Cibus Inc’s earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research before making financial decisions.